IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF

被引：0

作者：

Kao, Jia-Horng ^{[1
]}

Chuang, Wan-Long ^{[2
]}

Chen, Chi-Yi ^{[3
]}

Ahn, Sang Hoon ^{[4
]}

Fung, Scott K. ^{[5
]}

Elkhashab, Magdy ^{[6
]}

Hann, Hie-Won L. ^{[7
]}

Ravendhran, Natarajan ^{[8
]}

Nguyen, Tuan T. ^{[9
]}

Tan, Susanna ^{[10
]}

Flaherty, John F. ^{[10
]}

Gagger, Anuj ^{[10
]}

Gao, Bing ^{[10
]}

Brainard, Diana M. ^{[10
]}

Phan, Charles G. ^{[11
]}

Lim, Young-Suk ^{[12
]}

Ferret, Maria Asuncion Buti ^{[13
]}

Lampertico, Pietro ^{[14
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, Kaohsiung, Taiwan

[3] Chia Yi Christian Hosp, Dept Internal Med, Chiayi, Taiwan

[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea

[5] Univ Toronto, Toronto, ON, Canada

[6] Toronto Liver Ctr, Res, Toronto, ON, Canada

[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[8] Digest Dis Associates PA, Wyomissing, PA USA

[9] T Nguyen Res & Educ Inc, San Diego, CA USA

[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[11] Mem Hermann Sugar Land, Sugar Land, TX USA

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea

[13] Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit, Barcelona, Spain

[14] Fdn Irccs Ca Granda Osped Maggiore Policlin, CRC AM & A Migliavacca Ctr Liver Dis, Div Gastroenterol & Hepatol, Milan, Italy

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

795

引用

页码：484A / 484A

页数：1

共 50 条

[21] A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96 [J].

Agarwal, K. ;

Fung, S. ;

Seto, W. K. ;

Lim, Y. S. ;

Gane, E. ;

Janssen, H. L. ;

Sharma, M. ;

Chuang, W. L. ;

Bae, H. ;

Yoon, K. T. ;

Flaherty, J. F. ;

Lau, A. ;

Gaggar, A. ;

Suri, V. ;

Cathcart, A. ;

Lin, L. ;

Subramanian, G. M. ;

Shalimar ;

Furusyo, N. ;

Buti, M. ;

Chan, H. L. .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :S478-S478

[22] BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF) [J].

Buti, Maria ;

Gane, Edward J. ;

Agarwal, Kosh ;

Wong, Grace Lai-Hung C. ;

Lim, Young-Suk ;

Chen, Chi-Yi ;

Lim, Seng Gee ;

Yatsuhashi, Hiroshi ;

Fung, Scott K. ;

Abramov, Frida ;

Wang, Hongyuan ;

Yee, Leland J. ;

Flaherty, John F. ;

Pan, Calvin Q. ;

Marcellin, Patrick .

HEPATOLOGY, 2023, 78 :S507-S509

[23] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY [J].

Agarwal, Kosh ;

Fung, Scott ;

Seto, Wai-Kay ;

Lim, Young-Suk ;

Gane, Edward ;

Janssen, Harry L. ;

Chuang, Wan-Long ;

Bae, Ho ;

Yoon, Ki Tae ;

Flaherty, John F. ;

Lau, Audrey ;

Gaggar, Anuj ;

Suri, Vithika ;

Cathcart, Andrea ;

Lin, Lanjia ;

Chan, Alain ;

Shalimar, Mani Subramanian ;

Furusyo, Norihiro ;

Buti, Maria ;

Chan, Henry L. .

GASTROENTEROLOGY, 2017, 152 (05) :S1085-S1086

[24] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS [J].

Chan, Henry Lik Yuen ;

Lampertico, Pietro ;

Buti, Maria ;

Fung, Scott ;

Ahn, Sang Hoon ;

Chuang, Wan-Long ;

Tak, Won Young ;

Ramji, Alnoor ;

Chen, Chi-Yi ;

Tam, Edward ;

Bae, Ho ;

Ma, Xiaoli ;

Flaherty, John ;

Gaggar, Anuj ;

Lau, Audrey ;

Feierbach, Becket ;

Wu, George ;

Suri, Vithika ;

Subramanian, Mani ;

Huy Trinh ;

Yoon, Seung-Kew ;

Agarwal, Kosh ;

Lim, Young-Suk .

GUT, 2019, 68 :A142-A143

[25] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) [J].

Chan, Henry Lik Yuen ;

Lim, Young-Suk ;

Seto, Wai Kay ;

Ning, Qin ;

Agarwal, Kosh ;

Janssen, Harry L. A. ;

Pan, Calvin O. ;

Chuang, Wan Long ;

Izumi, Namiki ;

Fung, Scott ;

Shalimar ;

Brunetto, Maurizia ;

Flaherty, John ;

Mo, Shuyuan ;

Cheng, Cong ;

Lin, Lanjia ;

Gaggar, Anuj ;

Subramanian, Mani ;

Marcellin, Patrick ;

Gane, Edward ;

Hou, Jinlin ;

Buti, Maria .

GUT, 2020, 69 :A75-A76

[26] Tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switches: real-world observation of impact on lipid profiles [J].

Banks, T. ;

Ashton, K. ;

Ustianowski, A. ;

Uriel, A. .

HIV MEDICINE, 2020, 21 :56-57

[27] CHRONIC HBV PATIENTS WHO SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) AFTER EITHER 2 OR 3 YEARS OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DEMONSTRATED IMPROVEMENT IN BONE AND RENAL SAFETY [J].

Buti, Maria ;

Izumi, Namiki ;

Lim, Young-Suk ;

Janssen, Harry L. ;

Kao, Jia-Horng ;

Streinu-Cercel, Adrian ;

Nurmukhametova, Elena ;

Ma, Xiaoli ;

Tabak, Omer ;

Jablkowski, Maciej ;

Suri, Vithika ;

Flaherty, John F. ;

Lau, Audrey H. ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Chowdhury, Abhijit ;

Fung, Scott ;

Chuang, Wan-Long ;

Gane, Edward .

GASTROENTEROLOGY, 2019, 156 (06) :S1195-S1196

[28] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) [J].

Lim, Young-Suk ;

Chan, Henry Lik Yuen ;

Seto, Wai-Kay ;

Ning, Qing ;

Agarwal, Kosh ;

Janssen, Harry L. A. ;

Pan, Calvin Q. ;

Chuang, Wan Long ;

Izumi, Namiki ;

Fung, Scott K. ;

Shalimar ;

Brunetto, Maurizia R. ;

Flaherty, John F. ;

Mo, Shuyuan ;

Cheng, Cong ;

Lin, Lanjia ;

Gaggar, Anuj ;

Subramanian, Mani ;

Marcellin, Patrick ;

Gane, Edward J. ;

Hou, Jinlin ;

Buti, Maria .

HEPATOLOGY, 2019, 70 :126A-127A

[29] FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT [J].

Gane, Edward J. ;

Buti, Maria ;

Fung, Scott K. ;

Chan, Henry Lik Yuen ;

Izumi, Namiki ;

Chuang, Wan Long ;

Ahn, Sang Hoon ;

Mehta, Rajiv M. ;

Gurel, Selim ;

Abramov, Frida ;

Yee, Leland J. ;

Wang, Hongyuan ;

Mateo, Roberto ;

Flaherty, John F. ;

Ma, Xiaoli ;

Pan, Calvin Q. ;

Lim, Young-Suk ;

Marcellin, Patrick .

HEPATOLOGY, 2023, 78 :S519-S520

[30] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB) [J].

Lampertico, Pietro ;

Buti, Maria ;

Fung, Scott ;

Ahn, Sang Hoon ;

Chuang, Wan-Long ;

Tak, Won Young ;

Ramji, Alnoor ;

Chen, Chi-Yi ;

Tam, Edward ;

Bae, Ho ;

Ma, Xiaoli ;

Flaherty, John F. ;

Gaggar, Anuj ;

Lau, Audrey H. ;

Feierbach, Becket ;

Wu, George ;

Suri, Vithika ;

Subramanian, Mani ;

Trinh, Huy N. ;

Yoon, Seung-Kew ;

Agarwal, Kosh ;

Lim, Young-Suk ;

Chan, Henry L. .

GASTROENTEROLOGY, 2019, 156 (06) :S1195-S1195

← 1 2 3 4 5 →